Endocrine * Flashcards
Other agents for DM *
Dopamine agonists- Bromocriptine
-MOA unknown
-Modest a1c decrease
Bile acid sequestration-colesevelam
Sodium glucose cotransportor 2 inhibitors *
Drugs- canagliflozin (invokana) dapagliflozin (farxiga) empagliflozin (jardiance), ertugliflozin (steglatro)
Uses- DM and CHF
MOA- sodium glucose co transporter 2 is responsible for transposing glucose in the kidney, this inhibits it increasing urinary glucose excretion
ADE-UTI, yeast infection, hypotension, bone fracture, Fournier gangrene
Alpha glucosidase inhibitors *
Drugs- acarbose, miglitol (glyset)
Uses- DM
MOA- enzyme breaks down carbs into glucose and other sugars that can be absorbed this inhibits this function; delays digestion of carbs, does not cause hypoglycemic
ADE- GI distress, flatulence, diarrhea, cramping
DO NOT USE IN IBD, colonic ulcers, obstruction
Thiazolidinediones *
Drugs- pioglitazone (actos), rosiglitazone (avandia)
Uses- DM
MOA- lower insulin resistance by acting as agonist for peroxisome proliferator activated receptor Y which regulates transcription of several insulin receptors
Not used a lot due to CV ADE
ADE- weight gain, increased SQ fat, osteopenia, fractures, increased risk of bladder cancer, liver toxicity, fluid tension
DO NOT ISE IN CHF
BLACK BOX WARNINF FOR RISIGLITAZONE- INCREASED RISK OF MI/ANGINA
Dipeptidyl peptidase 4 inhibitors *
Drugs- alogliptin (nesina), linaglipton (tradjenta), saxagliptin (onglyza), sitagliptin (januvia)
Uses- DM
MOA- inhibits DPP4 which is responsible for inactivating GLP1
so do not use with GLP1
ADE- HA, nasopharyngitis, hypersensitivity
Saxa can increase risk for CHF exacerbation
Sulfonylureas *
Drugs- glyburide (diabeta, glynase), glipizide (glucotrol), glimepiride (amaryl)
Uses- DM
MOA- stimulation of insulin release from beta cell in pancreas, decrease hepatic glucose production, increase peripheral insulin sensitivity
ADE- hypoglycemia, hyper insulinemia, weight gain
Uses caution in kidney liver insufficiency,
Glipizide and glimepiride can be used for decreased renal function
Meglitinides *
Drugs- repaglinide, nateglinide
Uses- DM
MOA- stimulate insulin secretion, rapid onset
DO NOT USE WIRG SULFONYLUREAS
Take prior to meal
ADE- hypoglycemia, worker gain
D-D- sulfonylureas
DO NOT GIVEN IN LIVER INSUFFICIENCY
Amylin analog *
Drugs- pramlintide (symlin, SQ)
Uses- DM
MOA- Amylin is a hormone that is co secreted with insulin, delays gastric emptying, decrease post prandial glucagon secretion, improves satiety
ADE- n/v, anorexia
DO NOT MIX WITH INSULIN IN PREP
AVOID IN delayed gastric emptying, gastroparesis, cresol hypersensitivity, hypoglycemic unaware
Biguanides *
Drugs- metformin (glumetza, roimet)
Uses- DOC for initial therapy for DM or pre DM
MOA- decrease hepatic gluconeogenesis, slow intestinal absorption of sugars, improve peripheral glucose uptake, risk of hypoglycemia is less
ADE- GI, N/V/D, weight loss, decreases appetite
DO NOT GIVE IN severe renal function (GFR less than 30), DC in acute MI, CHF exacerbation, AKI, DO NOT GIVE WITH IV CONTRAST
Use caution for those over 80 years of age and alcohol abuse
GLP1 agonist *
Drugs- liraglutide (victoza), semaglutide (Ozempic, rybelsus), dulaglutide (trulicity), exanatide (Byetta, bydurdeon), lixisenatide (adlyxin)
Uses- DM, obesity
MOA- GLP 1 is important for appetite and food regulation, decrease hunger
Liragluride is QD
semaglutide is Q week injection
Semaglutide, dulaglutide, litaglutide also decrease CV risk in DM/CVD
ADE- n/v/d, constipation, avoid in chronic pancreatitis pts
BLACK BOX WARNING FOR THYROID CA RISK
Weight loss combination drugs *
Drug- Phentermine and topiramate (qsymia)
If not significant weight loss, greater than 5% in 12 weeks, then DC
DO NOT abrupt stop
Contraindicated in pregnancy
Drug- bupropion and naltrexone (contrave)
Contraindicated in HTN
Long acting insulin *
-insulin glargine (basaglar, lantus, semglee, toujeo)- slower, flat, prolonged effect
- insulin determir (levemir)- binds to albumin, slow dissociation
DO NOT MIX WITH OTHER INSULINS IN PREP
Combination insulin
70% NPH and 30% regular insulin
Goal for DM
A1C less than 7
Mean BG less than 154
Insulin (all types)
drugs- multiple-long acting, short acting, intermediate acting
MOA- replace absent secretion in type 1 or insufficient in type 2
ADE- hypoglycemia, weight gain, injection site reactions, lipodystrophy (rotate sites)